Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Pain. 2022 Jan 1;163(1):83–90. doi: 10.1097/j.pain.0000000000002298

Table 3:

Adjusted hazard ratios of opioid related events and adjusted odds ratios for buprenorphine fills in 12 months after discontinuation or dose reduction, according to opioid dose trajectory

Risk of any event Risk of suicide Risk of overdose Risk of Adverse events Buprenorphine Filled
aHR (95% CI)* aHR (95% CI)* aHR (95% CI)* aHR (95% CI)* aOR (95% CI)*
Stable or increasing dose Reference Reference Reference Reference Reference
Abrupt discontinuation 1.22 (0.94–1.58) 3.63 (1.42–9.25) 0.62 (0.40–0.94) 1.61 (1.15–2.26) 15.07 (7.28–38.38)
Dose reduction and discontinuation 1.13 (0.84–1.53) 4.47 (1.68–11.88) 0.36 (0.20–0.66) 1.54 (1.05–2.25) 14.83 (7.00–38.33)
Dose reduction without discontinuation 0.94 (0.73–1.21) 1.29 (0.48–3.45) 0.41 (0.27–0.62) 1.45 (1.04–2.02) 2.47 (1.14–6.46)

aHR: adjusted hazard ratio; OR: odds ratio, CI: confidence interval

*

Adjusted for age, gender, race, rurality, comorbidities, MME dose, filled benzodiazepines, chronic pain